UNISOUND AI TECHNOLOGY CO., LTD.

雲知聲智能科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9678)

VOLUNTARY ANNOUNCEMENT
LAUNCH OF THE U2-MED TRI-MEDICAL LLM

This announcement is made by Unisound AI Technology Co., Ltd. (the "**Company**") on a voluntary basis to inform the shareholders and potential investors of the Company of its latest business developments.

Recently, the Company completed the iterative upgrade of its medical large model based on the U2 foundation model and officially released the "U2-Med Tri-Medical LLM" (the "**Upgrade**"), the industry's first professional large model for the medical, medical insurance (including commercial insurance), and pharmaceutical sectors. The Upgrade further strengthens the Company's model capabilities in professional fields and promotes the technological iteration of high-value Token scenarios. The model is expected to be widely embedded in the core processes related to the digital collaborative of tri-medical field, which will help accelerate the expansion of the Company's large model business and generate long-term, sustainable revenue contributions.

I. Core Model Capabilities

The U2-Med, relying on the Company's U2 large model foundation, has achieved significant improvements in computational efficiency and intelligent agent execution. As the industry's first industrial-grade large model to integrate the full-chain capabilities of the "tri-medical", U2-Med incorporates the Company's decade of deep experience in the medical field. It breaks down data and business silos across healthcare, medical insurance and pharmaceuticals, and supports the digital transformation of the tri-medical field with an integrated capability, comprehensively covering professional task scenarios across the broader medical sector.

U2-Med delves deep into the core business processes of the tri-medical sectors, bringing tangible capability and efficiency improvements to clinicians, insurance practitioners, and pharmaceutical practitioners: for doctors, the model has capabilities such as assisted diagnosis and treatment, medical record generation, and identification of risks in clinical and electronic documents; for medical insurance and commercial insurance, the model can accurately identify questionable points such as use of medication beyond prescribed limits, duplicate charges, and excessive treatment, supports DRG/DIP compliance reviews, and helps audit personnel focus on key verifications; for the pharmaceutical industry, the model assists with pre-screening of trial subjects, verification of indications and contraindications, and risk alerts for concomitant medications, among other functions. This upgrade has truly achieved intelligent synergy across the tri-medical field, integrating clinical diagnosis and treatment, medical insurance payment, and pharmaceutical supply in a one-stop manner, while addressing the core pain points of the industry, including low cross-sector collaboration efficiency, fragmented control and high labour costs.

II. Evaluation Results

In the July 2026 MedBench Evaluation, U2-Med models ranked first on the two leaderboards for full-modality large models and intelligent agents. It also leads in the "Tri-Medical Comprehensive Benchmark" for real-world business scenarios, achieving a comprehensive score of 89.1 in non-thinking mode and 88.9 in thinking mode. Its scores for specific tasks were 93.3 for medical record generation and quality control, 94.1 for post-diagnosis and medication management, and 88.8 for medical and commercial insurance tasks. The evaluation data fully demonstrates that U2-Med is not merely a general theoretical medical model, but a commercial-grade professional model that is aligned with real-world business processes. Its technical capabilities can be directly translated into tangible value for industrial deployment.

III. Commercialization and AGI Vision

Following the Upgrade, U2-Med will be deeply embedded into a wider range of tri-medical domain-wide business processes, creating higher industry value with its "expert-level" capabilities while replacing repetitive tasks to unleash the professional potential of tri-medical practitioners. The Company will also continue to promote its large-scale implementation in the tri-medical field, accelerating the positive flywheel of industry data accumulation and model iteration, continuously strengthening its business moat and injecting long-term momentum for the continuous release and commercial realization of high-value Tokens.

The Company firmly believes that the evolution of technology will always follow a path of inclusive benefit; the ultimate vision of AGI is to safeguard and enhance the well-being of the general public. This is precisely the core aspiration behind the Company's more than a decade of dedicated focus on the medical field — to transform cutting-edge intelligence into a core driving force for safeguarding public health and empowering industrial upgrading, using the power of "Intelligence for Advancement" to practice the value of "Intelligence for Good".

By Order of the Board
Unisound AI Technology Co., Ltd.
Dr. Huang Wei
Executive Director and Chief Executive Officer

Beijing, the PRC
July 17, 2026

As at the date of this announcement, the Board of Directors of the Company comprises: (i) Dr. Liang Jia'en, Dr. Huang Wei, Dr. Kang Heng, Dr. Li Xiaohan and Dr. Liu Shengping as executive directors; and (ii) Mr. Hu Jianjun, Dr. Fan Jian, Dr. Jin Huihua and Dr. Zhang Kun as independent non-executive Directors.